217 related articles for article (PubMed ID: 19243388)
1. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
Lather V; Kairys V; Fernandes MX
Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
[TBL] [Abstract][Full Text] [Related]
2. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
3. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
[TBL] [Abstract][Full Text] [Related]
5. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
[TBL] [Abstract][Full Text] [Related]
7. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Shibata Y; Kagechika K; Yamaguchi M; Kubo H; Usui H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7075-9. PubMed ID: 23084275
[TBL] [Abstract][Full Text] [Related]
9. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
10. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
11. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
Gani OA; Sylte I
Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
[TBL] [Abstract][Full Text] [Related]
12. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
Shibata Y; Kagechika K; Ota M; Yamaguchi M; Setoguchi M; Kubo H; Chiba K; Takano H; Akiyama C; Ono M; Nishi M; Usui H
Chem Pharm Bull (Tokyo); 2015; 63(8):591-602. PubMed ID: 26235167
[TBL] [Abstract][Full Text] [Related]
14. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
Maltarollo VG; Honório KM
Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
[TBL] [Abstract][Full Text] [Related]
15. Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.
Fresno N; Macías-González M; Torres-Zaguirre A; Romero-Cuevas M; Sanz-Camacho P; Elguero J; Pavón FJ; Rodríguez de Fonseca F; Goya P; Pérez-Fernández R
J Med Chem; 2015 Aug; 58(16):6639-52. PubMed ID: 26226490
[TBL] [Abstract][Full Text] [Related]
16. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
17. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
